Back to Search Start Over

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Authors :
Rodon J
Perez-Fidalgo A
Krop I
Burris H
Guerrero-Zotano A
Britten C
Becerra C
Schellens J
Richards D
Schuler M
Abu-Khalaf M
Johnson F
Ranson M
Edenfield J
Silva A
Hackl W
Quadt C
Demanse D
Duval V
Baselga J
Source :
CANCER CHEMOTHERAPY AND PHARMACOLOGY, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Publication Year :
2018
Publisher :
SPRINGER, 2018.

Details

ISSN :
14320843
Database :
OpenAIRE
Journal :
CANCER CHEMOTHERAPY AND PHARMACOLOGY, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Accession number :
edsair.RECOLECTA.....6302117b10c4545840a4581d2686ac99

Tools

Authors Abstract Subjects Details